Taizhou Hanzhong biomedical co. LTD
11
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
27%
3 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Role: lead
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
Role: lead
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
Role: lead
Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
Role: lead
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
Role: lead
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Role: lead
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
Role: lead
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Role: lead
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Role: lead
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Role: lead
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
Role: lead
All 11 trials loaded